Leinco Technologies

Anti-Mouse CD19 - DyLight® 550

Product Code:
 
LEI-C2110
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG2a
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
1D3
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C2110-50ug50 ug£159.00
Quantity:
LEI-C2110-100ug100 ug£211.00
Quantity:
LEI-C2110-200ug200 ug£291.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Antigen Distribution:
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 550
Format:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Fusion of NS-1 Myeloma cells with spleen cells
Long Description:
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.
NCBI Gene:
12478
Target:
CD19